AGS-16M8F
/ Astellas, Pfizer
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 02, 2018
Phase 1 Trials of anti-ENPP3 antibody drug conjugates in advanced refractory renal cell carcinomas.
(PubMed, Clin Cancer Res)
- "AGS-16C3F was tolerated and had durable antitumor activity at 1.8 mg/kg every 3 weeks."
Journal • P1 data
1 to 1
Of
1
Go to page
1